Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and MEA 2b

imatinib mesylate has been researched along with MEA 2b in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nevins, JR; Wells, SA1
de Groot, JW; Drenth-Diephuis, LJ; Eggen, BJ; Hofstra, RM; Links, TP; Osinga, J; Plaza Menacho, I; Plukker, JT; Schepers, H1

Other Studies

2 other study(ies) available for imatinib mesylate and MEA 2b

ArticleYear
Evolving strategies for targeted cancer therapy--past, present, and future.
    Journal of the National Cancer Institute, 2004, Jul-07, Volume: 96, Issue:13

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Medullary; DNA, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Thyroidectomy

2004
Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    Surgery, 2006, Volume: 139, Issue:6

    Topics: Apoptosis; Benzamides; Carcinoma, Medullary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-ret; Pyrimidines; Thyroid Neoplasms

2006